Navigation Links
Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Date:10/11/2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... ... 2015 , ... As part of its 2015 growth plan and as a follow up to ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on a ... Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP 62 ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... , , , , , Mark Churchill ... , , , , , ... The data presented here can be acquired using , a Thermo Finnigan ... Introduction , , , , , ...
... , , , RohanA.Thakur, AndrewW. Guzzetta, and Julie , ... , Ion Trap Analysis , , , , ... LCQ Advantage, LCQ Deca XP, and Deca XP Plus ion , trap mass spectrometer., ... , , , , , Two important considerations in ...
... , , , , ... Center for Neurologic Diseases, Brigham and Womens Hospital, Harvard , ... , , Genetic manipulations using neuronal cells are notoriously ... , to primary neuronal cultures is of critical importance for ...
Cached Biology Technology:Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 2Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 3Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 4Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 5Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 6Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 7Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep , Technology 8Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN , siRNA and TransMessenger Transfection Reagent* 2Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN , siRNA and TransMessenger Transfection Reagent* 3Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN , siRNA and TransMessenger Transfection Reagent* 4Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN , siRNA and TransMessenger Transfection Reagent* 5
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... National Cancer Institute (NCI) has awarded Huntsman Cancer Institute investigator ... five years to continue studying the role of a gene ... devastating and sometimes deadly skin cancer. VanBrocklin is an assistant ... Utah. The majority of melanomas have mutations in a ...
... of the fastest-growing open-access scholarly publishers, now part of ... Frontiers in Cell and Developmental Biology journal ... One of the most exciting revolutions occurring in ... in Cell and Developmental Biology will provide a ...
... not want to live a long and healthy life? A ... from ETH Zurich have demonstrated in roundworms. Vitamin B3 ... the worms, diet caused them to live for about one ... of researchers headed by Michael Ristow, a professor of energy ...
Cached Biology News:Niacin, the fountain of youth 2
... an enzyme that catalyzes the hydrolysis ... maltotriose, and dextrins. The,level of a-amylase ... body is of,clinical significance in the ... diabetes; plant and microbial a-amylases are,important ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Biology Products: